Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07525635

Aspirin Dosing in Pregnancy

The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Preeclampsia Possible

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Early Phase 1

Primary location

NYU Langone Health

New York, 10016, United States

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant people prior to 17 weeks
  • Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates
  • Age 18-50 years
  • Singleton viable gestation
  • Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors.

Exclusion criteria

  • Undergoing glucose challenge test (GCT) at time of blood draw
  • Allergy or intolerance to aspirin
  • Antithrombotic or antiplatelet therapy
  • Anemia (hemoglobin <10 g/dl) or thrombocytopenia (platelet count <100,000), or thrombocytosis (platelet count >600,000)
  • Known hemorrhagic diathesis
  • Planned delivery outside of NYU

Treatment and study plan

Aspirin

Drug

81mg twice a day (162mg total)

Other names: Acetylsalicylic acid

Primary outcomes

  1. Measures of platelet aggregation assessed by Light Transmission Aggregometry (LTA)

    Time frame: Baseline, 4 weeks after initiation of aspirin

Secondary outcomes

  1. Change in serum thromboxane

    Time frame: Baseline, 4 weeks after initiation of aspirin

  2. Change in complete blood count

    Time frame: Baseline, 4 weeks after initiation of aspirin

  3. Change in Mean Platelet Volume (MPV)

    Time frame: Baseline, 4 weeks after initiation of aspirin

  4. Change in Platelet Distribution Width (PDW)

    Time frame: Baseline, 4 weeks after initiation of aspirin

  5. Change in Plateletcrit (PCT)

    Time frame: Baseline, 4 weeks after initiation of aspirin

  6. Change in Life's Essential 8 questionnaire

    Time frame: Baseline, 4 weeks after initiation of aspirin

    Life's Essential 8 (LE8) is a cardiovascular health scoring system from the American Heart Association that rates health from 0 to 100 based on diet, activity, smoking, sleep, BMI, cholesterol, blood sugar, and blood pressure. Scores indicate high cardiovascular health, 50-79 is moderate, and below 50 is low. A score of 100 is ideal, while 0 represents the lowest health condition, such as severe, uncontrolled risk factors.

Study contacts

Contact information is provided by the study sponsor or research team.

Christina A. Penfield, MD, MPH

CONTACT

[email protected]

646-754-2700

Lucia Muzzarelli

CONTACT

[email protected]

646-754-2760

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Registry information

Official study title

Aspirin Dosing and Platelet Phenotype in Pregnancy

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
Apr 13, 2026
Registry last updated
May 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.